Sun.Jan 09, 2022

article thumbnail

Abbott CEO Ford showcases new ‘biowearable’ line at CES

pharmaphorum

US medical device company Abbott has said it plans to launch a new range of ‘biowearable’ health devices aimed at consumers, in a move that builds on its expertise in glucose monitoring. The company’s chief executive – Robert Ford – made the announcement at the massive CES tech trade show in Las Vegas, a venue usually dedicated to new TVs, gaming equipment, new smartphones and the like.

article thumbnail

Pheasants lose their cool after fighting

Scienmag

Pheasants lose their cool after fighting Credit: Credit Tim Fawcett Pheasants lose their cool after fighting Pheasants’ heads cool rapidly as they prepare to fight – then heat up afterwards, new research shows. Scientists from the University of Exeter used thermal cameras to watch juvenile pheasants, to see how their temperature changed during aggressive interactions […].

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA OPDP Look Back at 2021 – The Yawning Gap

Eye on FDA

Once again it was a quiet year with respect to the FDA’s Office of Prescription Drug Programs (OPDP). As noted in the past, there are two primary means for understanding the agency’s latest thinking with respect to promotional communications from pharmaceutical companies – the content and pattern of enforcement and the issuance of guidance documents to shed light on the parameters that exist.

article thumbnail

Hyperbolic metamaterials: Fusing artificial structures to natural 2D materials

Scienmag

Hyperbolic metamaterials (HMMs), which have an extremely high anisotropy with a hyperbolic dispersion relation, are rising as an innovative method of manipulating light. HMMs have received tremendous interest in photonics for their applicability to various fields such as super-resolution imaging, negative refraction, and emission engineering. In particular, the development of 2D natural hyperbolic materials, which […].

article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

New patent expiration for Allergan drug ALPHAGAN P

Drug Patent Watch

Annual Drug Patent Expirations for ALPHAGAN+P Alphagan P is a drug marketed by Allergan and is included in two NDAs. It is available from one supplier. There are eight patents…. The post New patent expiration for Allergan drug ALPHAGAN P appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Unintended consequences of edicts to wear a mask

Scienmag

University of Leeds Press Release Under embargo until 00.01 (United Kingdom time) on Monday 10 January 2022 Statistical Analysis Unintended consequences of edicts to wear a mask Governments need to be careful about the messaging around compulsory mask wearing to ensure the policy is fully effective, say researchers. When officials in Bangladesh announced a legal […].

More Trending

article thumbnail

New £10m centre to explore links between organisms and their microbiomes

Scienmag

The £10m Leverhulme Centre for the Holobiont aims to create a green revolution in agriculture, rescue threatened species, and restore habitats. The Centre, which has been awarded funding over ten years by the Leverhulme Trust, is led by a network of researchers across Imperial College London and includes partners at the Wellcome Sanger Institute, the […].

article thumbnail

Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2022

BioTech 365

Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2022 Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2022 – Revenue of $1,471.

52
article thumbnail

Psychological distress may lead to more care and high medical costs for adolescent and young adult cancer survivors

Scienmag

New research indicates that psychological distress from cancer and its treatment can cause many adolescent and young adult (AYA) cancer survivors to seek additional care and burden them with considerable medical expenses. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society. Compared with individuals without a history of […].

article thumbnail

NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets

BioTech 365

NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets Evaluation of NBTXR3 for global registration in priority head and neck cancer pathway proceeds with the first European patient randomized … Continue reading →

52
article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

article thumbnail

Which pharmaceutical companies have the most drug patents in Malaysia?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most patents in Malaysia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Malaysia? appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference

BioTech 365

DGAP-News: MorphoSys AG / Key word(s): Conference 10.01.2022 / 08:00 The issuer is solely responsible for the content of this announcement. Media Release Planegg/Munich, Germany, January 10, 2022 MorphoSys To Present At the 40th Annual J.P.

40
article thumbnail

908 Devices Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021

BioTech 365

908 Devices Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021 908 Devices Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021 Full year 2021 revenue growth of at least 54% compared to 2020 BOSTON–(BUSINESS WIRE)–908 … Continue reading →

52
article thumbnail

Pharmaron Acquires Commercial API Manufacturing Facility in the United Kingdom from Recipharm

BioTech 365

Pharmaron Acquires Commercial API Manufacturing Facility in the United Kingdom from Recipharm Pharmaron Acquires Commercial API Manufacturing Facility in the United Kingdom from Recipharm Continues to strengthen the global chemistry and manufacturing capabilities and capacities BEIJING–(BUSINESS WIRE)–Pharmaron Beijing Co.

article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue and Provides 2022 Revenue Outlook

BioTech 365

Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue and Provides 2022 Revenue Outlook Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue and Provides 2022 Revenue Outlook Full year 2021 commercial … Continue reading →

40
article thumbnail

HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated B-Cell Non-Hodgkin Lymphoma in China

BioTech 365

HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated B-Cell Non-Hodgkin Lymphoma in China HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated B-Cell Non-Hodgkin Lymphoma in China — HMPL-760 is the … Continue reading →

40
article thumbnail

IsoPlexis Reports Preliminary Full Year 2021 Revenue, Releases Industry-First Superhuman Cell Library

BioTech 365

IsoPlexis Reports Preliminary Full Year 2021 Revenue, Releases Industry-First Superhuman Cell Library IsoPlexis Reports Preliminary Full Year 2021 Revenue, Releases Industry-First Superhuman Cell Library Superhero cells are key to the efficacy, potency, and durability of therapies across the human health spectrum BRANFORD, … Continue reading →

40
article thumbnail

Zymergen Announces Emerging Drug Discovery Business Enabled by One of the World’s Largest Metagenomics Databases and Proprietary Synthetic Biology Platform

BioTech 365

Zymergen Announces Emerging Drug Discovery Business Enabled by One of the World’s Largest Metagenomics Databases and Proprietary Synthetic Biology Platform Zymergen Announces Emerging Drug Discovery Business Enabled by One of the World’s Largest Metagenomics Databases and Proprietary Synthetic Biology Platform … Continue reading →

Drugs 40
article thumbnail

Accelerating Clinical Supply Through Integrated Drug Development

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

article thumbnail

NanoString Provides Preliminary Financial and Operational Highlights for Fourth Quarter and FY 2021

BioTech 365

NanoString Provides Preliminary Financial and Operational Highlights for Fourth Quarter and FY 2021 NanoString Provides Preliminary Financial and Operational Highlights for Fourth Quarter and FY 2021 – Record Q4 Product and Service Revenue of $42 Million, Including GeoMx Revenue of … Continue reading →

article thumbnail

NanoString Announces Commercial Leadership Transition

BioTech 365

NanoString Announces Commercial Leadership Transition NanoString Announces Commercial Leadership Transition Chad Brown to Retire Following More than Four Successful Years as SVP, Sales & Marketing Genomics and Diagnostics Veteran John D.

Genome 52
article thumbnail

Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collaboration to Develop Novel Patented Molecular Signatures for Rheumatoid Arthritis Biologic Therapeutic Selection

BioTech 365

Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collaboration to Develop Novel Patented Molecular Signatures for Rheumatoid Arthritis Biologic Therapeutic Selection Exagen Inc.

article thumbnail

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates

BioTech 365

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates – Achieved Full Year 2021 Preliminary … Continue reading →

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

#news #biotech Neurimmune inks US-$760 deal with AstraZeneca

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Neurimmune inks US-$760 deal with AstraZeneca. from European Biotechnology – first and foremost in European biotech [link].

article thumbnail

Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Financial Guidance, and Outlines Key Priorities and Milestones for 2022

BioTech 365

Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Financial Guidance, and Outlines Key Priorities and Milestones for 2022 Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Financial Guidance, and Outlines … Continue reading →

52
article thumbnail

Emergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 Results

BioTech 365

Emergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 Results Emergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 Results Expects a re-baseline of operations with stable revenue contributions from core products and services business in 2022, guiding to total … Continue reading →

article thumbnail

RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Financial and Operational Results

BioTech 365

RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Financial and Operational Results RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Financial and Operational Results ALISO VIEJO, Calif., Jan.

40
article thumbnail

The New Clinical Trial Supply Chain: Resilient, Flexible, and Patient-Centric

The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.